BlackRock Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

BlackRock Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14K	Hold	23	–	–	﹤0.01%	3517
2016 Q3	$26K	Buy	23 +14	+156%	+$15.1K	﹤0.01%	3396
2016 Q2	$10K	Hold	9	–	–	﹤0.01%	3578
2016 Q1	$11K	Hold	9	–	–	﹤0.01%	3565
2015 Q4	$21K	Buy	+9	New	+$13.8K	﹤0.01%	3481
2015 Q2	–	Sell	-24	Closed	-$25K	–	3754
2015 Q1	$25K	Buy	24 +4	+20%	+$13.2K	﹤0.01%	3404
2014 Q4	$66K	Sell	20 -1	-5%	-$3.07K	﹤0.01%	3215
2014 Q3	$62K	Sell	21 -6	-22%	-$19.8K	﹤0.01%	3213
2014 Q2	$101K	Buy	+27	New	+$102K	﹤0.01%	3047

Other funds holding NBSE

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SIP

Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

BlackRock Advisors's NBSE Position: Q4 2016 in Review

BlackRock Advisors held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q4 2016 at 23 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

BlackRock Advisors first reported a position in NBSE in Q2 2014 and has held it in 9 quarters since. The position peaked at $101K in Q2 2014. 49 funds tracked by Wall St. Rank hold NBSE as of Q4 2016.

BlackRock Advisors held 23 shares of NeuBase Therapeutics, Inc. Common Stock worth $14K as of Q4 2016.
BlackRock Advisors left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3517 holding.
BlackRock Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 9 quarters since.
BlackRock Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $101K in Q2 2014.
49 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.